Skip to main content

Table 1 Comparison of general clinical data between the two groups

From: The safety of antithrombotic therapy in patients with cerebral microbleeds and cardiogenic cerebral embolism due to nonvalvular atrial fibrillation

  CMBs group n = 110 non-CMBs group n = 122 t orχ2 P value
Patient characteristics
 Male gender (%) 81 (73.6) 74 (60.7) 4.396 0.036
 Age (years) 68.1 ± 11.4 68.0 ± 13.0 0.039 0.969
 Smoking (%) 36 (32.7) 49 (40.2) 1.378 0.240
 Hypertension history (%) 81 (73.6) 72 (59.0) 5.506 0.019
 Diabetes history (%) 48 (43.6) 37 (30.3) 4.413 0.036
AF status 6.380 0.012
 AF history (%) 56 (50.9) 82 (67.2)   
 New diagnosis of AF (%) 54 (49.1) 40 (32.8)   
AF type 0.045 0.833
 Paroxysmal AF (%) 40 (36.4) 46 (37.7)   
 Persistent AF (%) 70 (63.6) 76 (62.3)   
 CI history (%) 22 (20.0) 21 (17.2) 0.298 0.585
 CH history (%) 4 (3.6) 2 (1.6) 0.916 0.339
NIHSS score 6.3 ± 5.2 7.1 ± 5.6 −0.864 0.389
CHA2DS2VASc score 5.0 ± 1.2 5.4 ± 1.2 −2.922 0.004
HAS-BLED score 1.6 ± 0.4 1.5 ± 0.5 0.152 0.880
Antithrombotic therapy 11.981 0.001
 Anticoagulant therapy 54 (49.1) 87 (71.3) 1.180 0.554
 Warfarin (%) 14 (12.7) 30 (24.6)   
 Dabigatran (%) 36 (32.7) 52 (42.6)   
 Rivaroxaban (%) 4 (3.6) 5 (4.1)   
 Antiplatelet therapy 56 (50.9) 35 (28.7) 0.005 0.946
 Aspirin (%) 34 (30.9) 21 (17.2)   
 Clopidogrel (%) 22 (20.0) 14 (11.5)